Mass Drug Administration Trial to Eliminate Lymphatic Filariasis in Papua New Guinea: Changes in Microfilaremia, Filarial Antigen, and Bm14 Antibody after Cessation
Identifieur interne : 006A29 ( Main/Exploration ); précédent : 006A28; suivant : 006A30Mass Drug Administration Trial to Eliminate Lymphatic Filariasis in Papua New Guinea: Changes in Microfilaremia, Filarial Antigen, and Bm14 Antibody after Cessation
Auteurs : Daniel J. Tisch ; Moses J. Bockarie ; Zachary Dimber ; Benson Kiniboro ; Nandao Tarongka ; Fred E. Hazlett ; Will Kastens ; Michael P. Alpers ; James W. KazuraSource :
- The American journal of tropical medicine and hygiene [ 0002-9637 ] ; 2008.
Descripteurs français
- KwdFr :
- Animaux, Anticorps antihelminthe (sang), Antigènes d'helminthe (sang), Antiparasitaires (administration et posologie), Antiparasitaires (usage thérapeutique), Association de médicaments, Diéthylcarbamazine (usage thérapeutique), Enfant, Enfant d'âge préscolaire, Filariose lymphatique (), Filariose lymphatique (immunologie), Filariose lymphatique (traitement médicamenteux), Filariose lymphatique (épidémiologie), Humains, Ivermectine (administration et posologie), Ivermectine (usage thérapeutique), Nourrisson, Papouasie - Nouvelle-Guinée (épidémiologie), Wuchereria bancrofti (immunologie), Wuchereria bancrofti (isolement et purification), Études de suivi.
- MESH :
- administration et posologie : Antiparasitaires, Ivermectine.
- immunologie : Filariose lymphatique, Wuchereria bancrofti.
- isolement et purification : Wuchereria bancrofti.
- sang : Anticorps antihelminthe, Antigènes d'helminthe.
- traitement médicamenteux : Filariose lymphatique.
- usage thérapeutique : Antiparasitaires, Diéthylcarbamazine, Ivermectine.
- épidémiologie : Filariose lymphatique, Papouasie - Nouvelle-Guinée.
- Animaux, Association de médicaments, Enfant, Enfant d'âge préscolaire, Filariose lymphatique, Humains, Nourrisson, Études de suivi.
- Wicri :
- geographic : Papouasie-Nouvelle-Guinée.
English descriptors
- KwdEn :
- Animals, Antibodies, Helminth (blood), Antigens, Helminth (blood), Antiparasitic Agents (administration & dosage), Antiparasitic Agents (therapeutic use), Child, Child, Preschool, Diethylcarbamazine (therapeutic use), Drug Therapy, Combination, Elephantiasis, Filarial (drug therapy), Elephantiasis, Filarial (epidemiology), Elephantiasis, Filarial (immunology), Elephantiasis, Filarial (prevention & control), Follow-Up Studies, Humans, Infant, Ivermectin (administration & dosage), Ivermectin (therapeutic use), Papua New Guinea (epidemiology), Wuchereria bancrofti (immunology), Wuchereria bancrofti (isolation & purification).
- MESH :
- chemical , administration & dosage : Antiparasitic Agents, Ivermectin.
- chemical , blood : Antibodies, Helminth, Antigens, Helminth.
- chemical , therapeutic use : Antiparasitic Agents, Diethylcarbamazine, Ivermectin.
- geographic , epidemiology : Papua New Guinea.
- drug therapy : Elephantiasis, Filarial.
- epidemiology : Elephantiasis, Filarial.
- immunology : Elephantiasis, Filarial, Wuchereria bancrofti.
- isolation & purification : Wuchereria bancrofti.
- prevention & control : Elephantiasis, Filarial.
- Animals, Child, Child, Preschool, Drug Therapy, Combination, Follow-Up Studies, Humans, Infant.
Abstract
Laboratory tools to monitor infection burden are important to evaluate progress and determine endpoints in programs to eliminate lymphatic filariasis. We evaluated changes in
Url:
PubMed: 18256431
PubMed Central: 2590750
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream Pmc, to step Corpus: 002759
- to stream Pmc, to step Curation: 002758
- to stream Pmc, to step Checkpoint: 003936
- to stream PubMed, to step Corpus: 003385
- to stream PubMed, to step Curation: 003385
- to stream PubMed, to step Checkpoint: 003385
- to stream Ncbi, to step Merge: 002B62
- to stream Ncbi, to step Curation: 002B62
- to stream Ncbi, to step Checkpoint: 002B62
- to stream Main, to step Merge: 006B29
- to stream Main, to step Curation: 006A29
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Mass Drug Administration Trial to Eliminate Lymphatic Filariasis in Papua New Guinea: Changes in Microfilaremia, Filarial Antigen, and Bm14 Antibody after Cessation</title><author><name sortKey="Tisch, Daniel J" sort="Tisch, Daniel J" uniqKey="Tisch D" first="Daniel J." last="Tisch">Daniel J. Tisch</name></author><author><name sortKey="Bockarie, Moses J" sort="Bockarie, Moses J" uniqKey="Bockarie M" first="Moses J." last="Bockarie">Moses J. Bockarie</name></author><author><name sortKey="Dimber, Zachary" sort="Dimber, Zachary" uniqKey="Dimber Z" first="Zachary" last="Dimber">Zachary Dimber</name></author><author><name sortKey="Kiniboro, Benson" sort="Kiniboro, Benson" uniqKey="Kiniboro B" first="Benson" last="Kiniboro">Benson Kiniboro</name></author><author><name sortKey="Tarongka, Nandao" sort="Tarongka, Nandao" uniqKey="Tarongka N" first="Nandao" last="Tarongka">Nandao Tarongka</name></author><author><name sortKey="Hazlett, Fred E" sort="Hazlett, Fred E" uniqKey="Hazlett F" first="Fred E." last="Hazlett">Fred E. Hazlett</name></author><author><name sortKey="Kastens, Will" sort="Kastens, Will" uniqKey="Kastens W" first="Will" last="Kastens">Will Kastens</name></author><author><name sortKey="Alpers, Michael P" sort="Alpers, Michael P" uniqKey="Alpers M" first="Michael P." last="Alpers">Michael P. Alpers</name></author><author><name sortKey="Kazura, James W" sort="Kazura, James W" uniqKey="Kazura J" first="James W." last="Kazura">James W. Kazura</name></author></titleStmt><publicationStmt><idno type="wicri:source">PMC</idno><idno type="pmid">18256431</idno><idno type="pmc">2590750</idno><idno type="url">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2590750</idno><idno type="RBID">PMC:2590750</idno><date when="2008">2008</date><idno type="wicri:Area/Pmc/Corpus">002759</idno><idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Corpus" wicri:corpus="PMC">002759</idno><idno type="wicri:Area/Pmc/Curation">002758</idno><idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Curation">002758</idno><idno type="wicri:Area/Pmc/Checkpoint">003936</idno><idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Checkpoint">003936</idno><idno type="wicri:source">PubMed</idno><idno type="wicri:Area/PubMed/Corpus">003385</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">003385</idno><idno type="wicri:Area/PubMed/Curation">003385</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">003385</idno><idno type="wicri:Area/PubMed/Checkpoint">003385</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">003385</idno><idno type="wicri:Area/Ncbi/Merge">002B62</idno><idno type="wicri:Area/Ncbi/Curation">002B62</idno><idno type="wicri:Area/Ncbi/Checkpoint">002B62</idno><idno type="wicri:doubleKey">0002-9637:2008:Tisch D:mass:drug:administration</idno><idno type="wicri:Area/Main/Merge">006B29</idno><idno type="wicri:Area/Main/Curation">006A29</idno><idno type="wicri:Area/Main/Exploration">006A29</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en" level="a" type="main">Mass Drug Administration Trial to Eliminate Lymphatic Filariasis in Papua New Guinea: Changes in Microfilaremia, Filarial Antigen, and Bm14 Antibody after Cessation</title><author><name sortKey="Tisch, Daniel J" sort="Tisch, Daniel J" uniqKey="Tisch D" first="Daniel J." last="Tisch">Daniel J. Tisch</name></author><author><name sortKey="Bockarie, Moses J" sort="Bockarie, Moses J" uniqKey="Bockarie M" first="Moses J." last="Bockarie">Moses J. Bockarie</name></author><author><name sortKey="Dimber, Zachary" sort="Dimber, Zachary" uniqKey="Dimber Z" first="Zachary" last="Dimber">Zachary Dimber</name></author><author><name sortKey="Kiniboro, Benson" sort="Kiniboro, Benson" uniqKey="Kiniboro B" first="Benson" last="Kiniboro">Benson Kiniboro</name></author><author><name sortKey="Tarongka, Nandao" sort="Tarongka, Nandao" uniqKey="Tarongka N" first="Nandao" last="Tarongka">Nandao Tarongka</name></author><author><name sortKey="Hazlett, Fred E" sort="Hazlett, Fred E" uniqKey="Hazlett F" first="Fred E." last="Hazlett">Fred E. Hazlett</name></author><author><name sortKey="Kastens, Will" sort="Kastens, Will" uniqKey="Kastens W" first="Will" last="Kastens">Will Kastens</name></author><author><name sortKey="Alpers, Michael P" sort="Alpers, Michael P" uniqKey="Alpers M" first="Michael P." last="Alpers">Michael P. Alpers</name></author><author><name sortKey="Kazura, James W" sort="Kazura, James W" uniqKey="Kazura J" first="James W." last="Kazura">James W. Kazura</name></author></analytic><series><title level="j">The American journal of tropical medicine and hygiene</title><idno type="ISSN">0002-9637</idno><idno type="eISSN">1476-1645</idno><imprint><date when="2008">2008</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Animals</term><term>Antibodies, Helminth (blood)</term><term>Antigens, Helminth (blood)</term><term>Antiparasitic Agents (administration & dosage)</term><term>Antiparasitic Agents (therapeutic use)</term><term>Child</term><term>Child, Preschool</term><term>Diethylcarbamazine (therapeutic use)</term><term>Drug Therapy, Combination</term><term>Elephantiasis, Filarial (drug therapy)</term><term>Elephantiasis, Filarial (epidemiology)</term><term>Elephantiasis, Filarial (immunology)</term><term>Elephantiasis, Filarial (prevention & control)</term><term>Follow-Up Studies</term><term>Humans</term><term>Infant</term><term>Ivermectin (administration & dosage)</term><term>Ivermectin (therapeutic use)</term><term>Papua New Guinea (epidemiology)</term><term>Wuchereria bancrofti (immunology)</term><term>Wuchereria bancrofti (isolation & purification)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Animaux</term><term>Anticorps antihelminthe (sang)</term><term>Antigènes d'helminthe (sang)</term><term>Antiparasitaires (administration et posologie)</term><term>Antiparasitaires (usage thérapeutique)</term><term>Association de médicaments</term><term>Diéthylcarbamazine (usage thérapeutique)</term><term>Enfant</term><term>Enfant d'âge préscolaire</term><term>Filariose lymphatique ()</term><term>Filariose lymphatique (immunologie)</term><term>Filariose lymphatique (traitement médicamenteux)</term><term>Filariose lymphatique (épidémiologie)</term><term>Humains</term><term>Ivermectine (administration et posologie)</term><term>Ivermectine (usage thérapeutique)</term><term>Nourrisson</term><term>Papouasie - Nouvelle-Guinée (épidémiologie)</term><term>Wuchereria bancrofti (immunologie)</term><term>Wuchereria bancrofti (isolement et purification)</term><term>Études de suivi</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Antiparasitic Agents</term><term>Ivermectin</term></keywords><keywords scheme="MESH" type="chemical" qualifier="blood" xml:lang="en"><term>Antibodies, Helminth</term><term>Antigens, Helminth</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antiparasitic Agents</term><term>Diethylcarbamazine</term><term>Ivermectin</term></keywords><keywords scheme="MESH" type="geographic" qualifier="epidemiology" xml:lang="en"><term>Papua New Guinea</term></keywords><keywords scheme="MESH" qualifier="administration et posologie" xml:lang="fr"><term>Antiparasitaires</term><term>Ivermectine</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Elephantiasis, Filarial</term></keywords><keywords scheme="MESH" qualifier="epidemiology" xml:lang="en"><term>Elephantiasis, Filarial</term></keywords><keywords scheme="MESH" qualifier="immunologie" xml:lang="fr"><term>Filariose lymphatique</term><term>Wuchereria bancrofti</term></keywords><keywords scheme="MESH" qualifier="immunology" xml:lang="en"><term>Elephantiasis, Filarial</term><term>Wuchereria bancrofti</term></keywords><keywords scheme="MESH" qualifier="isolation & purification" xml:lang="en"><term>Wuchereria bancrofti</term></keywords><keywords scheme="MESH" qualifier="isolement et purification" xml:lang="fr"><term>Wuchereria bancrofti</term></keywords><keywords scheme="MESH" qualifier="prevention & control" xml:lang="en"><term>Elephantiasis, Filarial</term></keywords><keywords scheme="MESH" qualifier="sang" xml:lang="fr"><term>Anticorps antihelminthe</term><term>Antigènes d'helminthe</term></keywords><keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Filariose lymphatique</term></keywords><keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Antiparasitaires</term><term>Diéthylcarbamazine</term><term>Ivermectine</term></keywords><keywords scheme="MESH" qualifier="épidémiologie" xml:lang="fr"><term>Filariose lymphatique</term><term>Papouasie - Nouvelle-Guinée</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Animals</term><term>Child</term><term>Child, Preschool</term><term>Drug Therapy, Combination</term><term>Follow-Up Studies</term><term>Humans</term><term>Infant</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Animaux</term><term>Association de médicaments</term><term>Enfant</term><term>Enfant d'âge préscolaire</term><term>Filariose lymphatique</term><term>Humains</term><term>Nourrisson</term><term>Études de suivi</term></keywords><keywords scheme="Wicri" type="geographic" xml:lang="fr"><term>Papouasie-Nouvelle-Guinée</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en"><p id="P2">Laboratory tools to monitor infection burden are important to evaluate progress and determine endpoints in programs to eliminate lymphatic filariasis. We evaluated changes in <italic>Wuchereria bancrofti</italic> microfilaria, filarial antigen and Bm14 antibody in individuals who participated in a five-year mass drug administration trial in Papua New Guinea. Comparing values before treatment and one year after four annual treatments, the proportion of microfilaria positive individuals declined to the greatest degree, with less marked change in antibody and antigen rates. Considering children as sentinel groups who reflect recent transmission intensity, children surveyed before the trial were more frequently microfilaria and antibody positive than those examined one year after the trial stopped. In contrast, antigen positive rates were similar in the two groups. All infection indicators continued to decline five years after cessation of mass drug administration; Bm14 antibody persisted in the greatest proportion of individuals. These data suggest that Bm14 antibody may be a sensitive test to monitor continuing transmission during and after mass drug administration aimed at eliminating transmission of lymphatic filariasis.</p></div></front></TEI><affiliations><list></list><tree><noCountry><name sortKey="Alpers, Michael P" sort="Alpers, Michael P" uniqKey="Alpers M" first="Michael P." last="Alpers">Michael P. Alpers</name><name sortKey="Bockarie, Moses J" sort="Bockarie, Moses J" uniqKey="Bockarie M" first="Moses J." last="Bockarie">Moses J. Bockarie</name><name sortKey="Dimber, Zachary" sort="Dimber, Zachary" uniqKey="Dimber Z" first="Zachary" last="Dimber">Zachary Dimber</name><name sortKey="Hazlett, Fred E" sort="Hazlett, Fred E" uniqKey="Hazlett F" first="Fred E." last="Hazlett">Fred E. Hazlett</name><name sortKey="Kastens, Will" sort="Kastens, Will" uniqKey="Kastens W" first="Will" last="Kastens">Will Kastens</name><name sortKey="Kazura, James W" sort="Kazura, James W" uniqKey="Kazura J" first="James W." last="Kazura">James W. Kazura</name><name sortKey="Kiniboro, Benson" sort="Kiniboro, Benson" uniqKey="Kiniboro B" first="Benson" last="Kiniboro">Benson Kiniboro</name><name sortKey="Tarongka, Nandao" sort="Tarongka, Nandao" uniqKey="Tarongka N" first="Nandao" last="Tarongka">Nandao Tarongka</name><name sortKey="Tisch, Daniel J" sort="Tisch, Daniel J" uniqKey="Tisch D" first="Daniel J." last="Tisch">Daniel J. Tisch</name></noCountry></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/LymphedemaV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 006A29 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 006A29 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= LymphedemaV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= PMC:2590750
|texte= Mass Drug Administration Trial to Eliminate Lymphatic Filariasis in Papua New Guinea: Changes in Microfilaremia, Filarial Antigen, and Bm14 Antibody after Cessation
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:18256431" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a LymphedemaV1
| This area was generated with Dilib version V0.6.31. |  |